Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.
On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback